Baseline Hepatic SIRT1 and Gut‑Derived Bile Acid Signaling Predict Individual Response to Berberine‑Induced AMPK Activation

Hypothesis

Individuals with higher baseline hepatic SIRT1 activity and a gut microbiome enriched for bile‑acid‑transforming bacteria (e.g., Bacteroides vulgatus, Clostridium scindens) will exhibit greater berberine‑stimulated AMPK phosphorylation, leading to larger reductions in fasting glucose and HbA1c. Conversely, low SIRT1 or a microbiome lacking 7α‑dehydroxylating capacity will blunt AMPK activation and attenuate metabolic benefits.

Rationale

Berberine lowers glucose primarily via AMPK activation [3]. AMPK activity is modulated by cellular NAD⁺ levels, which are regulated by SIRT1 deacetylase; SIRT1 can directly activate LKB1, the upstream kinase of AMPK [1]. Gut microbiota influence host bile acid pools; secondary bile acids such as deoxycholic acid (DCA) act as agonists of TGR5 and FXR, pathways that cross‑talk with AMPK to enhance insulin sensitivity [7]. Prior work shows berberine reshapes the microbiome [4], but no study has linked baseline bile‑acid‑metabolizing capacity to the magnitude of AMPK activation.

Predictions

1. Baseline hepatic SIRT1 mRNA (measured in peripheral blood mononuclear cells as a surrogate) will positively correlate with the change in p‑AMPK/AMPK ratio after 4 weeks of berberine (1 g/day).
2. Stool metagenomic enrichment for B. vulgatus and C. scindens (genes for bile‑acid 7α‑dehydroxylase) will predict a larger fall in fasting plasma glucose (≥0.8 mmol/L) and HbA1c (≥0.5%).
3. Participants with both high SIRT1 and a bile‑acid‑transforming microbiome will show additive glucose lowering, whereas those low in either factor will show minimal change (<0.2 mmol/L glucose reduction).

Experimental Design

• Population: 60 adults with prediabetes (FPG 100–125 mg/dL) not on glucose‑lowering medication.
• Baseline measurements: hepatic SIRT1 expression (qPCR from PBMCs), serum LPS, fasting glucose/HbA1c, stool shotgun metagenomics for bile‑acid‑gene abundance.
• Intervention: Berberine hydrochloride 500 mg twice daily for 12 weeks.
• Outcomes: Change in FPG, HbA1c, and p‑AMPK/AMPK ratio in PBMCs at week 4 and week 12.
• Analysis: Multivariate regression testing SIRT1 and microbiome scores as independent predictors of glucose change; interaction term to assess synergy.

Potential Outcomes and Falsifiability

• Support: Significant positive regression coefficients for SIRT1 (β > 0.3, p < 0.01) and bile‑acid‑gene abundance (β > 0.25, p < 0.01), with a significant interaction (p < 0.05) indicating greater effect when both are high.
• Refutation: No significant association between either baseline SIRT1 or microbiome biomarkers and glucose or AMPK changes (p > 0.1), or a negative correlation, would falsify the hypothesis.

This framework extends existing AMPK‑centric models by incorporating host SIRT1 status and microbial bile‑acid metabolism as predictive, mechanistic layers that explain inter‑individual variability in berberine response.